Burning Rock Dx(US:BNR) Zhi Tong Cai Jing·2026-01-15 15:24Core Viewpoint - After a significant stock price increase of 18.49%, Burning Rock Medical (BNR.US) saw an additional rise of over 10%, reaching $31.483, driven by the presentation of two research outcomes at the San Antonio Breast Cancer Symposium (SABCS) and ASCO Gastrointestinal Cancers Symposium (ASCO-GI), focusing on liquid biopsy technologies for breast cancer (BC) and colorectal cancer (CRC) [1] Group 1 - Burning Rock Medical showcased innovative clinical applications of liquid biopsy technology for low-abundance mutation detection and minimal residual disease (MRD) detection, contributing to advancements in precision oncology [1] - Traditional tissue biopsies are invasive and do not meet the long-term monitoring needs for BC, while liquid biopsies offer a minimally invasive alternative by analyzing ctDNA in blood [1] - The company developed OncoCompass, a super deep targeted sequencing technology combined with machine learning, aimed at improving the accuracy and reliability of low-abundance ctDNA detection [1][2] Group 2 - OncoCompass effectively addresses the core challenges of monitoring treatment efficacy and warning of recurrence in BC, providing a practical mutation detection tool for patients with low tumor burden [2] - The integration of super deep sequencing technology with machine learning represents a breakthrough in overcoming the technical bottlenecks of low-abundance ctDNA detection, further expanding the application boundaries of liquid biopsy in precision oncology [2]